Coya Therapeutics (COYA) Competitors $6.26 +0.49 (+8.39%) Closing price 03:52 PM EasternExtended Trading$6.05 -0.22 (-3.50%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA vs. ETON, HUMA, RZLT, UPXI, ARCT, CMPX, ATXS, SNDL, GOSS, and MBXShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Eton Pharmaceuticals (ETON), Humacyte (HUMA), Rezolute (RZLT), Upexi (UPXI), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), Astria Therapeutics (ATXS), SNDL (SNDL), Gossamer Bio (GOSS), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Its Competitors Eton Pharmaceuticals Humacyte Rezolute Upexi Arcturus Therapeutics Compass Therapeutics Astria Therapeutics SNDL Gossamer Bio MBX Biosciences Coya Therapeutics (NASDAQ:COYA) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Does the media refer more to COYA or ETON? In the previous week, Coya Therapeutics and Coya Therapeutics both had 5 articles in the media. Eton Pharmaceuticals' average media sentiment score of 0.44 beat Coya Therapeutics' score of 0.44 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, COYA or ETON? Coya Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Do analysts rate COYA or ETON? Coya Therapeutics currently has a consensus price target of $16.67, indicating a potential upside of 166.03%. Eton Pharmaceuticals has a consensus price target of $29.67, indicating a potential upside of 104.25%. Given Coya Therapeutics' higher possible upside, equities research analysts plainly believe Coya Therapeutics is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, COYA or ETON? Eton Pharmaceuticals has higher revenue and earnings than Coya Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.55M29.52-$14.88M-$1.07-5.86Eton Pharmaceuticals$39.01M9.99-$3.82M-$0.18-80.69 Do institutionals and insiders believe in COYA or ETON? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by company insiders. Comparatively, 16.0% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is COYA or ETON more profitable? Coya Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -9.49%. Eton Pharmaceuticals' return on equity of -3.15% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -48.88% -43.32% Eton Pharmaceuticals -9.49%-3.15%-1.08% SummaryEton Pharmaceuticals beats Coya Therapeutics on 8 of the 13 factors compared between the two stocks. Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.67M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-5.8621.5627.4020.04Price / Sales29.52281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book2.647.518.085.67Net Income-$14.88M-$55.05M$3.16B$248.47M7 Day Performance6.19%3.16%2.12%2.90%1 Month Performance10.88%5.92%4.43%5.75%1 Year Performance3.73%5.82%35.62%21.36% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics2.3495 of 5 stars$6.27+8.4%$16.67+166.0%-4.5%$96.67M$3.55M-5.866Analyst ForecastETONEton Pharmaceuticals2.6827 of 5 stars$13.51-0.4%$29.67+119.6%+341.5%$363.91M$39.01M-75.0620HUMAHumacyte2.3542 of 5 stars$2.21-4.3%$11.71+430.1%-54.8%$358.32M$1.57M-3.20150Gap DownRZLTRezolute3.01 of 5 stars$4.03-1.9%$11.83+193.6%+15.4%$351.48MN/A-3.5040UPXIUpexi3.4693 of 5 stars$10.00+8.1%$16.00+60.0%-68.0%$350.72M$26M0.00130Upcoming EarningsGap UpARCTArcturus Therapeutics3.7723 of 5 stars$12.51+1.8%$53.50+327.7%-36.6%$333.31M$152.31M-4.94180News CoverageAnalyst ForecastCMPXCompass Therapeutics3.213 of 5 stars$2.54+5.8%$13.13+416.7%+197.7%$331.88M$850K-6.2020News CoverageAnalyst UpgradeATXSAstria Therapeutics1.4564 of 5 stars$5.61-4.3%$30.00+434.8%-36.1%$330.70MN/A-3.0030News CoverageSNDLSNDL3.3196 of 5 stars$1.24-0.8%$3.63+192.3%-33.5%$328.47M$927.61M-4.282,516Positive NewsGOSSGossamer Bio3.6312 of 5 stars$1.37-4.9%$7.75+465.7%+26.1%$327.32M$124.59M-5.96180MBXMBX Biosciences2.4106 of 5 stars$9.73-0.1%$37.50+285.4%N/A$325.22MN/A0.0036 Related Companies and Tools Related Companies Eton Pharmaceuticals Competitors Humacyte Competitors Rezolute Competitors Upexi Competitors Arcturus Therapeutics Competitors Compass Therapeutics Competitors Astria Therapeutics Competitors SNDL Competitors Gossamer Bio Competitors MBX Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COYA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COYA Stock Alerts